MRM Mass Spectrometry Platform Overview​

Multiple Reaction Monitoring Mass Spectrometry (MRM-MS) focuses on quantification of predefined highly-multiplexed sets of proteins with high sensitivity, specificity and reproducibility. This method is well suited for detection of abundance changes in a large set of proteins in a single analysis. Changes in protein abundance can be used to stratify disease states, optimize therapeutic selection, and determine prognosis. MRM-MS is ideal for researchers asking, “What happens to my proteins of interest?”​ Since there is no need for expensive and time-consuming antibody development, this approach offers significant time and cost savings over antibody-based methods. MRM-MS has significant advantages over immunoassays, in particular in multiplexing capability, specificity, and eliminating the need for expensive and time-consuming generation of custom reagents. Reference: Kearney et al. Curr Opin Biotechnol 2018; 51:123-129.

Key Benefits of LC-MS at Biodesix​



• Blood-based classifier designed to identify low-to-moderate risk patients with a likely benign lung nodule​ • Classifier integrates plasma proteins with clinical risk factors associated with lung cancer


Lung Cancer Protein Panel​

Alzheimer’s Protein Panel​​

Custom MRM-MS Protein Panel​

  • Biodesix also offers highly-multiplexed custom protein panels and custom assay development for your protein targets of interest.​
  • Experience developing MRM-MS assays with over 1,600 peptides.​
  • No need for expensive and time-consuming antibody development with an MRM-MS approach.

Unbiased DIA LC-MS/MS​

  • Biodesix’s unbiased (hypothesis-free) proteomic biomarker discovery workflow leverages high-resolution LC-MS/MS to analyze the proteome of large numbers of samples to identify proteins (e.g. peptide biomarkers or targets) that exhibit differential expression between the study groups of interest.
  • Instrumentation and methods are selected to match the goals of each study.

Direct Neoantigen Characterization

  • Directly profile and quantitate MHC-presented peptides with LC-MS.
  • In contrast to in silico peptide sequence prediction models, LC-MS provides direct physical evidence that a peptide is actually present on the cell surface (and therefore amenable to interaction with a TCR).

Get in touch

Contact us